At close: December 13 at 4:00:02 PM EST
After hours: December 13 at 7:10:17 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 3 | 4 |
| Avg. Estimate | 0.16 | 0.05 | 0.22 | 0.24 |
| Low Estimate | 0.05 | 0.05 | 0.07 | 0.13 |
| High Estimate | 0.35 | 0.05 | 0.5 | 0.39 |
| Year Ago EPS | 0 | -0.02 | -6.27 | 0.22 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 3 | 6 | 6 |
| Avg. Estimate | 92.5M | 81.9M | 353.42M | 348.4M |
| Low Estimate | 89M | 79.9M | 350M | 302M |
| High Estimate | 96.7M | 85.7M | 357.6M | 375.8M |
| Year Ago Sales | 117.55M | 74.88M | 442.74M | 353.42M |
| Sales Growth (year/est) | -21.31% | 9.38% | -20.17% | -1.42% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.2 | 0.15 | 0.14 | 0.1 |
| EPS Actual | 0 | -0.02 | 0 | 0.02 |
| Difference | -0.2 | -0.17 | -0.14 | -0.08 |
| Surprise % | -100.00% | -113.33% | -100.00% | -79.49% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.16 | 0.05 | 0.22 | 0.24 |
| 7 Days Ago | 0.07 | 0.07 | 0.12 | 0.33 |
| 30 Days Ago | 0.07 | 0.07 | 0.12 | 0.33 |
| 60 Days Ago | 0.07 | 0.07 | 0.12 | 0.33 |
| 90 Days Ago | 0.07 | 0.07 | 0.12 | 0.33 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | 1 | -- | -- | 1 |
| Down Last 30 Days | 1 | -- | 4 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| IRWD | 0.00% | 350.00% | 103.46% | 11.92% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Initiated | Leerink Partners: Market Perform | 9/9/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 8/9/2024 |
| Maintains | Craig-Hallum: Buy to Buy | 8/9/2024 |
| Maintains | Craig-Hallum: Buy to Buy | 5/10/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/1/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 2/16/2024 |
Related Tickers
SUPN Supernus Pharmaceuticals, Inc.
36.17
+0.03%
COLL Collegium Pharmaceutical, Inc.
30.09
0.00%
PCRX Pacira BioSciences, Inc.
19.86
+0.30%
SIGA SIGA Technologies, Inc.
6.18
+0.49%
ETON Eton Pharmaceuticals, Inc.
12.35
+1.56%
ALKS Alkermes plc
30.51
+0.03%
SCYX SCYNEXIS, Inc.
1.1400
+2.70%
AVDL Avadel Pharmaceuticals plc
10.39
-2.07%
ITCI Intra-Cellular Therapies, Inc.
83.03
-0.44%
EVO Evotec SE
4.4900
-2.81%